Rottinghaus Scott T. 4
4 · ENANTA PHARMACEUTICALS INC · Filed Jul 15, 2024
Insider Transaction Report
Form 4
Rottinghaus Scott T.
Chief Medical Officer
Transactions
- Exercise/Conversion
Common Stock
2024-07-15$8.99/sh+5,375$48,321→ 27,092 total - Sale
Common Stock
2024-07-15$17.08/sh−5,375$91,805→ 21,717 total - Exercise/Conversion
Stock Option (Right to Buy)
2024-07-15−5,375→ 80,625 totalExercise: $8.99Exp: 2033-11-22→ Common Stock (5,375 underlying) - Sale
Common Stock
2024-07-12$15.04/sh−2,271$34,156→ 21,717 total - Sale
Common Stock
2024-07-11$15.07/sh−4,299$64,786→ 23,988 total
Footnotes (5)
- [F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in March 2024.
- [F2]The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $15.00 to $15.155, inclusive.
- [F3]The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $15.00 to $15.16, inclusive.
- [F4]The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $17.00 to $17.21, inclusive.
- [F5]The option, representing a right to purchase a total of 86,000 shares, became or will become exercisable (subject to the optionholder's continued employment) quarterly in substantially equal installments (any fractional shares to be cumulated and to become exercisable at the end of the earliest succeeding quarterly period in which a whole share equivalent is accumulated) over four years from the date of grant (November 22, 2023).